BeiGene

Don’t miss out on the latest BeiGeneius Lung Cancer Academy webinar, which is available to watch on demand. Thank you to all the participants, and special thanks to our speakers, Luis Paz-Ares and Federico Cappuzzo. Healthcare professionals can visit https://ow.ly/YIaE50Uqcpr to access the webinar recording and additional resources.

This week, we hosted an R&D event reflecting on the data presented at #ASH24 and #SABCS24. The two-hour session featured key insights from our Co-Founder, Chairman and CEO John V. Oyler, Head of R&D Lai Wang, and our Chief Medical Officers, Mark Lanasa and Mehrdad Mobasher, covering our hematology franchise and solid tumor pipeline. We discussed our vision for the future of #CLL, highlighted the potential of our CDK4i, and shared our confidence in executing a deep and impactful pipeline. We're thrilled to receive positive feedback from the analysts who participated. To learn more about what is happening at BeiGene visit www.beigene.com. 

Since our beginning, BeiGene has been deeply committed to progressing new treatment options and research for patients with B-cell malignancies – no matter how rare. Yesterday, the FDA granted our BTK degrader orphan drug designation for the treatment of patients facing two types of rare blood cancers – Waldenström's macroglobulinemia (#WM) and follicular lymphoma (#FL). Learn about our Chimeric Degradation Activation Compound (#CDAC) technology and the trials we’re enrolling: https://ow.ly/E01G50UuA0J  

“Everything we do, we think about how it might impact the life and safety of patients.” Maria Isychou, our colleague in Basel, shares her patient-centered approach to working at BeiGene. Having a family member impacted by cancer, Maria brings a unique perspective on what it means to develop treatments that truly support patients around the world. Watch the video to learn more.

#News for #Investors and #Media: Our BTK inhibitor has been granted reimbursement in Poland for eligible patients with relapsed/refractory Marginal Zone Lymphoma (#MZL), marking its third indication approved for reimbursement in the country. This milestone underscores our ongoing commitment to helping more patients access our #oncology treatments across Europe and the world.

Understanding your unique genetic profile is crucial to managing chronic lymphocytic leukemia (#CLL) effectively. Approximately 50% of CLL patients have high-risk molecular features. Knowing your biomarker status provides insights into disease progression and helps guide healthcare providers in selecting the best treatment plan. Join us and CLL Society in encouraging patients to #TestBeforeTreat. Learn more at https://ow.ly/jZCz50UsaMH

As we close 2024 and approach the holidays, I wanted to take a moment to highlight the incredible impact of this year’s Light The Night walks. More than 500 BeiGene colleagues joined with the cancer community in 95 cities across the US to bring light to the darkness of cancer and stand with patients and families affected by blood cancer. Learn more about our collective efforts in partnership with The Leukemia & Lymphoma Society. #LightTheNight #PatientsFirst 

We’re thrilled to announce the first-ever grants from the BeiGene Foundation’s Access to Cancer Care Program! These grants empower global NGOs dedicated to making cancer care accessible for underserved communities.   Congratulations to our inaugural grant recipients: - Abrale - Associação Brasileira de Linfoma e Leucemia (Brazil): Ensuring blood cancer patients in Brazil have access to the best treatments. - Cancer Support Community (CSC) (USA): Strengthening support and advocacy for individuals impacted by cancer. - Department of Medical Services Foundation (Thailand): Advancing cancer screening and early diagnosis across Thailand. - Instituto Camaleão (Brazil): Empowering cancer patients through social reintegration and self-esteem support. - South African Clinical Haematology Society (SACHaS) (South Africa): Enhancing care for patients with hematological disorders.   We’re proud to support these outstanding organizations and the transformative impact they’re making in cancer care worldwide.   Stay tuned for updates on the programs they’re fueling in the coming months.   For more information about the BeiGene Foundation’s work, visit: https://ow.ly/TJ7K50UsbZX   #CancerCare #AccessToCare #EquityInHealth #CancerAwareness

ICYMI: We recently partnered with CLL Society to advance #TestBeforeTreat, a campaign emphasizing the importance of biomarker testing for patients with #CLL and #SLL. Together, we aim to educate patients and healthcare providers on the role of biomarker testing in guiding personalized care and improving outcomes. Read more in this Fierce Pharma article: https://bit.ly/49BUT1A

As the holiday season approaches, it's a special time to extend support to those facing the challenges of cancer. Simple gestures—whether through acts of kindness, lending a hand with daily tasks, offering emotional comfort, or sharing a festive treat—can show how much you care and bring a spark of hope. To all those affected by cancer, whether as patients or caregivers, we wish you peace, hope, and comfort this holiday season and beyond. You are not alone, and you matter deeply to us. For more insights, visit our #TalkAboutIt blog at https://ow.ly/p44p50Uqekk.